ZZL-7 is a fast-onset antidepressant agent. ZZL-7 works by disrupting the interaction between the serotonin transporter (SERT) and neuronal nitric oxide synthase (nNOS) in the dorsal raphe nucleus (DRN). ZZL-7 can cross the blood-brain barrier readily. ZZL-7 can be used for the research of major depressive disorder (MDD). In Vitro ZZL-7 (1.0 μM; or 2 h) incubation of the cultured 293T cells transfected with nNOS and SERT, significantly decreases the SERT-nNOS complex level. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo ZZL-7 (10 mg/kg, intraperitoneally) causes significantly increases firing frequency of serotonergic neurons 2 hours after treatment in vivo electrophysiology in SERT-Cre mice. In wild-type mice, ZZL-7 reduces immobility time . Intragastric administration of ZZL-7 (10, 20, and 40 mg/kg; once) produces antidepressant-like behaviors dose dependently 2 hours after treatment . ZZL-7 (10 mg/kg; intraperitoneal administration) reverses chronic unpredictable mild stress (CMS)-induced depressions behaviors 2 hours after treatment . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: SERT-Cre mice Dosage: 10 mg/kg Administration: i.p.; once Result: Significantly increased firing frequency of serotonergic neurons 2 hours after treatment in vivo electrophysiology in SERT-Cre mice. Form:Oil